383 related articles for article (PubMed ID: 28778402)
1. Epigenetics in myelodysplastic syndromes.
Heuser M; Yun H; Thol F
Semin Cancer Biol; 2018 Aug; 51():170-179. PubMed ID: 28778402
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
3. Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G; van der Reijden BA; Jansen JH
Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
[TBL] [Abstract][Full Text] [Related]
4. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
6. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
7. The myelodysplastic syndrome as a prototypical epigenetic disease.
Issa JP
Blood; 2013 May; 121(19):3811-7. PubMed ID: 23660859
[TBL] [Abstract][Full Text] [Related]
8. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; GarcĂa-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
9. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
[TBL] [Abstract][Full Text] [Related]
10. Genetics factors associated with myelodysplastic syndromes.
Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Epigenetic Modifications in Myeloid Malignancies.
Venney D; Mohd-Sarip A; Mills KI
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
[TBL] [Abstract][Full Text] [Related]
12. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
13. Genetics of myelodysplastic syndromes: new insights.
Graubert T; Walter MJ
Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics of myelodysplastic syndromes.
Itzykson R; Fenaux P
Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
[TBL] [Abstract][Full Text] [Related]
17. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
18. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Xu F; Li X
Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetic dysregulation and emerging treatment strategies in myelodysplastic syndromes].
Kunimoto H
Rinsho Ketsueki; 2024; 65(5):362-374. PubMed ID: 38825515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]